China Biologic Products to Present at Brean Murray, Carret 2010 China Growth Conference

PR Newswire
TAI'AN, China
Nov 15, 2010

TAI'AN, China, Nov. 15, 2010 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic," or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that the Company's management will present at the upcoming Brean Murray, Carret & Co. 2010 China Growth Conference.


        Date:            November 17, 2010
        Time:             09:20 a.m. EST
     Presenter: Ming Yin, Vice President - Finance
      Location:              Track II
                   The Millennium Broadway Hotel
                       145 West 44th Street
                     New York, New York 10036

The Brean Murray, Carret & Co. 2010 China Growth Conference is a two-day conference (November 17-18, 2010) that consists of 25-minute presentation slots followed by 10-minutes of open floor Q&A sessions with institutional investors. Senior management of presenting companies, industry experts, and institutional investors will receive a unique and comprehensive view of China from a global perspective. China Biologic's management will be available for 1x1 meetings before and after the Company's presentation.

About China Biologic Products, Inc.

China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biological Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently one of the leading plasma-based biopharmaceutical company in China. The Company is a fully integrated biological products company with plasma collection, production and manufacturing, research and development and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China.


                                   Company Contact:
                                     Mr. Ming Yin
                               Vice President - Finance
                             China Biologic Products, Inc.
                                 Tel: +86-851-3605846
                              Email: IR@chinabiologic.com
                                 www.chinabiologic.com

    Investor Relations Contact:
    Mr. Crocker Coulson, President
    CCG Investor Relations
    Phone: +1 (646) 213-1915
    Email: crocker.coulson@ccgir.com
    www.ccgirasia.com

SOURCE China Biologic Products, Inc.

SOURCE: China Biologic Products, Inc.

China Biologic Products to Present at Brean Murray, Carret 2010 China Growth Conference

PR Newswire

TAI'AN, China, Nov. 15, 2010 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic," or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that the Company's management will present at the upcoming Brean Murray, Carret & Co. 2010 China Growth Conference.

Date:

November 17, 2010

Time:

09:20 a.m. EST

Presenter:

Ming Yin, Vice President - Finance

Location:

Track II


The Millennium Broadway Hotel


145 West 44th Street


New York, New York 10036



The Brean Murray, Carret & Co. 2010 China Growth Conference is a two-day conference (November 17-18, 2010) that consists of 25-minute presentation slots followed by 10-minutes of open floor Q&A sessions with institutional investors. Senior management of presenting companies, industry experts, and institutional investors will receive a unique and comprehensive view of China from a global perspective. China Biologic's management will be available for 1x1 meetings before and after the Company's presentation.

About China Biologic Products, Inc.

China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biological Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently one of the leading plasma-based biopharmaceutical company in China. The Company is a fully integrated biological products company with plasma collection, production and manufacturing, research and development and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China.

Company Contact:

Mr. Ming Yin

Vice President - Finance

China Biologic Products, Inc.

Tel: +86-851-3605846

Email: IR@chinabiologic.com

www.chinabiologic.com


Investor Relations Contact:    

Mr. Crocker Coulson, President

CCG Investor Relations

Phone: +1 (646) 213-1915

Email: crocker.coulson@ccgir.com

www.ccgirasia.com



SOURCE China Biologic Products, Inc.

CONTACT: Mr. Ming Yin, Vice President - Finance of China Biologic Products, Inc., +86-851-3605846, IR@chinabiologic.com, or Investor Relations Contact: Mr. Crocker Coulson, President of CCG Investor Relations, +1-646-213-1915, crocker.coulson@ccgir.com

Web Site: http://www.chinabiologic.com